These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38520149)

  • 21. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    Bidulka P; Lugo-Palacios DG; Carroll O; O'Neill S; Adler AI; Basu A; Silverwood RJ; Bartlett JW; Nitsch D; Charlton P; Briggs AH; Smeeth L; Douglas IJ; Khunti K; Grieve R
    BMJ; 2024 May; 385():e077097. PubMed ID: 38719492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
    Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
    Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease.
    Pan HC; Chen JY; Chen HY; Yeh FY; Huang TT; Sun CY; Wang SI; Wei JC; Wu VC
    JAMA Netw Open; 2024 Jan; 7(1):e2350050. PubMed ID: 38170522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
    Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
    J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
    Khunti K; Kosiborod M; Kim DJ; Kohsaka S; Lam CSP; Goh SY; Chiang CE; Shaw JE; Cavender MA; Tangri N; Franch-Nadal J; Holl RW; Jørgensen ME; Norhammar A; Eriksson JG; Zaccardi F; Karasik A; Magliano DJ; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P;
    Cardiovasc Diabetol; 2021 Jul; 20(1):159. PubMed ID: 34332558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Pandey AK; Okaj I; Kaur H; Belley-Cote EP; Wang J; Oraii A; Benz AP; Johnson LSB; Young J; Wong JA; Verma S; Conen D; Gerstein H; Healey JS; McIntyre WF
    J Am Heart Assoc; 2021 Sep; 10(17):e022222. PubMed ID: 34459238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
    Sung HL; Hung CY; Tung YC; Lin CC; Tsai TH; Huang KH
    Diabetes Metab Res Rev; 2024 Mar; 40(3):e3784. PubMed ID: 38402457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
    Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin : A Cohort Study.
    Shin H; Schneeweiss S; Glynn RJ; Patorno E
    Ann Intern Med; 2022 Jul; 175(7):927-937. PubMed ID: 35605236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
    Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
    Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Metab; 2022 Nov; 48(6):101390. PubMed ID: 36170946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
    Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
    JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study.
    Engström A; Wintzell V; Melbye M; Hviid A; Eliasson B; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B; Ueda P
    Diabetes Care; 2023 Feb; 46(2):351-360. PubMed ID: 36508322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
    JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher long-term visit-to-visit glycemic variability predicts new-onset atrial fibrillation in patients with diabetes mellitus.
    Hsu JC; Yang YY; Chuang SL; Yu CC; Lin LY
    Cardiovasc Diabetol; 2021 Jul; 20(1):148. PubMed ID: 34301257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W; Chen X; Xie X; Xu M; Xu L; Liu P; Luo B
    J Cardiovasc Pharmacol; 2022 Mar; 79(3):281-288. PubMed ID: 34935705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sodium-glucose cotransporter-2 inhibitors protect against atrial fibrillation in patients with heart failure.
    Zhou L; Yang Y; Han W
    Ann Palliat Med; 2021 Oct; 10(10):10887-10895. PubMed ID: 34763450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Dapagliflozin on the Outcome of Radiofrequency Catheter Ablation in Patients with Type 2 Diabetes Mellitus and Atrial Fibrillation.
    Luo F; Sun L; Wang Z; Zhang Y; Li J; Chen Y; Dong J
    Cardiovasc Drugs Ther; 2024 Feb; 38(1):91-98. PubMed ID: 35962156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.